Streetwise Reports

The Gold Report

The Energy Report

The Life Sciences Report

Research Reports

Streetwise Reports

The Gold Report

The Energy Report

The Life Sciences Report

Research Reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Biopharma Co. Shows Large Potential Return

Research Report

Dr. Joseph Pantginis (10/21/2022)

Biopharma Co. Shows Large Potential Return

Palatin Technologies Inc.'s third-party clinical trial of Vyleesi in women with hypoactive sexual desire disorder was just published in the Journal of Clinical Investigation, and the biopharma offers investors significant potential return, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Biotech Co.'s Target Price Over Three Times Current

Research Report

Dr. Joseph Pantginis (10/13/2022)

Biotech Co.'s Target Price Over Three Times Current

Expanded interim data from the Phase 2 trial of this biotech's lead asset PDS0101 in HPV16-associated cancers are consistent with previously reported results from the same study. Read more to discover why H.C Wainright & Co. believes this stock is a Buy with a target price over three times the current.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co.'s Shares Roll to New 52-Week High Price

Streetwise Reports (10/12/2022)

Biopharma Co.'s Shares Roll to New 52-Week High Price

Shares of DICE Therapeutics Inc. traded 62% higher yesterday and established a new 52-week intraday high after the company reported positive topline data from its Phase 1 DC-806 Psoriasis study.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Partners With Merck for Combo Drug Trial

Research Report

Dr. Joseph Pantginis (10/12/2022)

Biopharma Co. Partners With Merck for Combo Drug Trial

With this and other clinical studies, the U.S. company has a busy and, thus, catalyst-rich Q4/22 ahead, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Chen Reveals His Picks for Last Quarter

Streetwise Reports (10/11/2022)

Chen Reveals His Picks for Last Quarter

Asset manager Chen Lin's picks for the home stretch of 2022 include several biotechs and some precious metals companies.

Tags: SilverBiotechnology / Pharmaceuticals

US Firm Teams up With Leading Pharma Co. To Delay T1D Onset

Streetwise Reports (10/07/2022)

US Firm Teams up With Leading Pharma Co. To Delay T1D Onset

Provention Bio Inc.'s shares traded 25% higher yesterday after the company reported it is joining forces with Sanofi U.S. to support the potential upcoming U.S. launch of its teplizumab for use in delaying the onset of clinical type 1 diabetes in at-risk patients. The U.S. FDA is expected to rule on the firm's Biologics License Application in mid-November 2022.

Tags: Biotechnology / Pharmaceuticals

Biotech Co.'s Drug Showing 'Early Signs of Benefit'

Research Report

Dr. Elemer Piros (10/06/2022)

Biotech Co.'s Drug Showing 'Early Signs of Benefit'

With this upcoming analysis, the board will determine whether the Phase 2b/3 trial may continue to completion, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Trial Results of New Drug for An Eye Disease 'Encouraging'

Research Report

Dr. Yale Jen (10/06/2022)

Trial Results of New Drug for An Eye Disease 'Encouraging'

The data suggest this treatment could be safer and more effective in treating proliferative vitreoretinopathy than compounded methotrexate, noted a Laidlaw & Co. report.

Tags: Biotechnology / Pharmaceuticals

Co. Uses RNA Editing as Treatment for Rare Disease

Research Report

Andrew Fein (10/03/2022)

Co. Uses RNA Editing as Treatment for Rare Disease

The firm plans to advance its alpha-1 antitrypsin deficiency program into the clinic next year, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Interim Results From Phase 2b Trial Are 'Encouraging'

Research Report

Dr. Elemer Piros (09/30/2022)

Interim Results From Phase 2b Trial Are 'Encouraging'

Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Awarded FDA Clearance for Advanced Solid Tumors Trial

Streetwise Reports (09/30/2022)

Biopharma Co. Awarded FDA Clearance for Advanced Solid Tumors Trial

Shares of oncology-focused biopharmaceutical company Immuneering Corp. traded 9% higher after the firm reported it received U.S. FDA clearance for its IND Application for a Phase 1/2a clinical trial of IMM-1-104 for use in treatment of advanced solid tumors with RAS mutations. The company expects to enroll the first patient in the study in Q4/22.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Meets Primary Endpoint in Phase 3 Alzheimer's Trial

Streetwise Reports (09/29/2022)

Pharma Co. Meets Primary Endpoint in Phase 3 Alzheimer's Trial

Shares of Eisai Co. Ltd. traded 58% higher yesterday after the company reported topline data from its global Phase 3 clinical study demonstrating that its lecanemab significantly met the primary and key secondary endpoints in reducing mild cognitive impairment due to Alzheimer's disease.

Tags: Biotechnology / Pharmaceuticals

Biopharma Asks for Emergent Use in US of New COVID Drug

Research Report

Edward White (09/29/2022)

Biopharma Asks for Emergent Use in US of New COVID Drug

The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Oncology Co.'s Shares Erupt on Signing Global License Deal

Streetwise Reports (09/27/2022)

Oncology Co.'s Shares Erupt on Signing Global License Deal

Shares of clinical-stage immuno-oncology company LAVA Therapeutics NV traded nearly 100% higher yesterday after the firm reported that it has entered into a global licensing agreement with Seagen Inc. to advance its LAVA-1223, a preclinical gamma delta bispecific T cell engager designed for use in the treatment of EGFR-expressing solid tumors.

Tags: Biotechnology / Pharmaceuticals

Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating

Research Report

Dr. Joseph Pantginis (09/23/2022)

Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating

To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Analyst Says Buy Before Biotech Co.'s Clinical Trials

Research Report

Dr. David Nierengarten (09/23/2022)

Analyst Says Buy Before Biotech Co.'s Clinical Trials

Argenx SE has "several upcoming catalysts," noted a Wedbush report.

Tags: Special SituationsBiotechnology / Pharmaceuticals

FDA Approves Hearing Loss Drug for Child Chemo Patients

Streetwise Reports (09/21/2022)

FDA Approves Hearing Loss Drug for Child Chemo Patients

Shares of Fennec Pharmaceuticals Inc. traded 14% higher after the company reported it received approval from the U.S. FDA for its PEDMARK® (sodium thiosulfate injection) for use in reducing the risk of ototoxicity in pediatric patients who are undergoing or completed chemotherapy for non-metastatic solid tumors.

Tags: Biotechnology / Pharmaceuticals

Important Catalyst Expected Soon for Cancer Drug Co.

Research Report

Dr. David Nierengarten (09/20/2022)

Important Catalyst Expected Soon for Cancer Drug Co.

The biopharma should announce initial clinical trial data on its lead small molecule candidate by year-end, noted a Wedbush report.

Tags: Biotechnology / Pharmaceuticals

Dermatology Co.'s Target Price Much Higher Than Current

Research Report

Dr. Jonathan Aschoff (09/20/2022)

Dermatology Co.'s Target Price Much Higher Than Current

The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers," noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co.'s Shares Rise on Phase 3 Migraine Trial Data

Streetwise Reports (09/20/2022)

Biopharma Co.'s Shares Rise on Phase 3 Migraine Trial Data

Satsuma Pharmaceuticals Inc. shares traded 12% higher to a new 52-week high after the company reported positive results from its Phase 3 long-term study of STS101 for use in acute treatment of migraine attacks. The company expects to receive further efficacy data from its Phase 3 SUMMIT trial in Q4/22, which it believes will support submission of an NDA with the U.S. FDA in Q1/23.

Tags: Biotechnology / Pharmaceuticals

Second Trial of New Eczema Drug To Commence in Q4/22

Research Report

Dr. Yi Chen (09/17/2022)

Second Trial of New Eczema Drug To Commence in Q4/22

The purpose behind this complementary study is to potentially expand the treatment's target patient population, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

FDA Grants Approval for Drug Improving Kidney Function

Streetwise Reports (09/16/2022)

FDA Grants Approval for Drug Improving Kidney Function

Shares of Mallinckrodt Plc. traded 28% higher yesterday after the company reported that the U.S. FDA has issued approval for its Terlivaz® (terlipressin) for injection for use in treating hepatorenal syndrome, a serious and life-threatening condition that is accompanied by rapid reduction in kidney function.

Tags: Biotechnology / Pharmaceuticals

Price Target on US Biopharma Co. Boosted by $15

Research Report

Julian Harrison (09/15/2022)

Price Target on US Biopharma Co. Boosted by $15

The increase came after positive clinical trial results on one of its lead drug candidates differentiating it from a competitor, noted a BTIG report.

Tags: Biotechnology / Pharmaceuticals

New Drug Shown To Help Patients With Desmoid Tumors

Research Report

Dr. David Nierengarten (09/15/2022)

New Drug Shown To Help Patients With Desmoid Tumors

This oral gamma-secretase inhibitor met the primary and secondary endpoints in a Phase 3 clinical trial, noted a Wedbush report.

Tags: Biotechnology / Pharmaceuticals

NDA for Dry Eye Disease Drug on Track for Q4/22 Submission

Research Report

Justin Kim (09/15/2022)

NDA for Dry Eye Disease Drug on Track for Q4/22 Submission

This and the biopharma's other treatment candidates for ocular diseases are underappreciated, which translates to an investment opportunity, noted an Oppenheimer report.

Tags: Biotechnology / Pharmaceuticals

Showing Results: 26 to 50 of 147 Prev Next

More Experts

"JEV appears to be technically at a very favorable entry point."

❭

– Clive Maund, CliveMaund.com

"For DV, we see significant growth potential around the Kitsol vein."

❭

– Geordie Mark, Haywood Securities

"Today's TLG drill results confirm the new high-grade 'Connector zone.'"

❭

– Jacques Wortman, Laurentian Bank Securities

"NAUs Resurrection Ridge is shaping up like it could host 1 Moz alone."

❭

– Thibaut Lepouttre, Caesars Report

"MAG has been the best performing silver stock in the past weeks."

❭

– Chen Lin, What Is Chen Buying? What Is Chen Selling?